BIMs were originally described in patients with germline inactivating BAP1 mutations, which cause an autosomal dominant tumour predisposition syndrome with increased risk of uveal melanoma, mesothelioma, meningioma, renal cell carcinoma, and cutaneous melanoma.6, 7, 8. This evidence concerns the gene BAP1 and uveal melanoma.